20055-01-0Relevant articles and documents
Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
Murano, Kenji,Yamanaka, Toshio,Toda, Ayako,Ohki, Hidenori,Okuda, Shinya,Kawabata, Kohji,Hatano, Kazuo,Takeda, Shinobu,Akamatsu, Hisashi,Itoh, Kenji,Misumi, Keiji,Inoue, Satoshi,Takagi, Tatsuya
, p. 2261 - 2275 (2008/12/20)
AmpC β-lactamase is one of the leading causes of Pseudomonas aeruginosa (P. aeruginosa) resistance to cephalosporins. FR259647 is a cephalosporin having a novel pyrazolium substituent at the 3-position and exhibits excellent activity (MIC = 1 μg/mL) again
CEPHEM COMPOUNDS
-
Page/Page column 33-34, (2010/02/11)
The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl or hydroxy (lower) alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower a
CEPHEM COMPOUNDS
-
Page 32 - 33, (2010/02/06)
The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.